Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.

Carella, Angelo Michele; Biasco, Samantha; Nati, Sandro; Congiu, Angela; Lerma, Enrica

Carella, Angelo Michele; Biasco, Samantha; Nati, Sandro; Congiu, Angela; Lerma, Enrica.

Leuk Lymphoma ; 48(3): 623-4, 2007 Mar.

Article in En | MEDLINE | ID: mdl-17454609

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Graft vs Host Disease/prevention & control; Immunosuppressive Agents/therapeutic use; Lymphoma, B-Cell/drug therapy; Steroids/therapeutic use; Adult; Antibodies, Monoclonal, Murine-Derived; Chronic Disease; Graft vs Host Disease/drug therapy; Humans; Male; Rituximab

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Steroids / Lymphoma, B-Cell / Graft vs Host Disease / Immunosuppressive Agents / Antibodies, Monoclonal / Antineoplastic Agents Limits: Adult / Humans / Male Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2007 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links